## In the Claims

Please amend the claims as follows:

1. (Currently Amended) A <u>mechanically stable</u> biphasic injectable composition comprising:

biocompatible micronized textured polyethylene particles having a size greater than sixty microns, and

a physiological carrier.

- 2. (Canceled)
- (Canceled)
- 4. (Currently Amended) The composition of Claim 1, wherein the <u>physiological</u> carrier is selected from polyvinylpyrrolidone, silicone oil, gelatin, collagen, fat, hyaluronic acid, saline, water or plasma.
  - 5. (Canceled)
  - 6. (Canceled)
- 7. (Currently Amended) The composition of Claim 1, wherein the <u>physiological</u> carrier is polyvinylpyrrolidone.
- 8. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.
- 9. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

- 10. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.
- 11. (Previously Presented) The composition of Claim 7, wherein the polyvinylpyrrolidone comprises a K value of 17.
  - 12. (Canceled)
- 13. (Currently Amended) The composition of Claim 1 wherein the biocompatible micronized textured polyethylene and the <u>physiological</u> carrier are combined at a ratio of approximately 3:2 <u>physiological</u> carrier to biocompatible micronized textured polyethylene by weight.
  - 14. (Canceled)
- 15. (Currently Amended) A method for tissue augmentation comprising:

  injecting a mechanically stable biphasic injectable composition comprising:

  solid-polymer particles wherein the solid polymer particles are mechanically stable and are suspended in a liquid carrier substrate.

biocompatible micronized textured polyethylene particles having a size greater than sixty microns, and

a physiological carrier.

- 16. (Cancelled)
- 17. (Currently Amended) The method of Claim 15, wherein the liquid physiological carrier substrate is selected from polyvinylpyrrolidone, silicone oil, gelatin, bovine collagen, autologous fat, hyaluronic acid, saline, water or autologous plasma.
  - 18. (Currently Amended) The method of Claim 15, wherein injecting comprises:

1290425\_1.DOC

inserting a delivery apparatus containing the <u>mechanically stable</u> biphasic injectable composition into the injection site.

- 19. (Withdrawn) The method of Claim 15, wherein the injecting comprises subcutaneous, intradermal, intramuscular, periurethral injection or injecting the vocal cords.
- 20. (Currently Amended) The composition of Claim 1, wherein the <u>biocompatible</u> micronized textured polyethylene particles textured particles have a size greater than eighty microns.
- 21. (Currently Amended) The composition of Claim 1, wherein the <u>biocompatible</u> micronized textured polyethylene particles textured particles have a size greater than one-hundred microns.
- 22. (Currently Amended) A <u>mechanically stable</u> biphasic injectable composition comprising:

biocompatible micronized textured polyethylene particles having a size of greater than sixty microns; and

- a physiological carrier comprising polyvinylpyrrolidone.
- 23. (Currently Amended) The composition of Claim 22 wherein the biocompatible micronized textured polyethylene and the <u>physiological</u> carrier are combined at a ratio of approximately 3:2 <u>physiological</u> carrier to biocompatible micronized textured polyethylene by weight.
- 24. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 100.
- 25. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 50.

- 26. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value from approximately less than 12 to 20.
- 27. (Previously Presented) The composition of Claim 22, wherein the polyvinylpyrrolidone comprises a K value of 17.
- 28. (Currently Amended) The composition of Claim 22, wherein the <u>biocompatible</u> micronized textured polyethylene particles textured particles have a size greater than eighty microns.
- 29. (Currently Amended) The composition of Claim 22, wherein the <u>biocompatible</u> micronized textured polyethylene particles textured particles have a size greater than one-hundred microns.